Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for GPCR ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 ...

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...